FDA commissioner Scott Gottlieb said: “Bringing new biosimilars to patients is a top priority for the FDA, and a key part of our efforts to help promote competition that can reduce drug costs an ...
The FDA Commissioner, Scott Gottlieb, also took the rare step of commenting on a new approval himself. “We’re entering a new frontier in medical innovation with the ability to reprogram a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback